Open AccessInflammatory bowel disease surgery in the biologic era
Author(s) -
Linda Ferrari,
Mukta Krane,
Alessandro Fichera
Publication year - 2016
Publication title -
world journal of gastrointestinal surgery
Language(s) - Uncategorized
Resource type - Journals
ISSN - 1948-9366
DOI - 10.4240/wjgs.v8.i5.363
Subject(s) - medicine , infliximab , adalimumab , ulcerative colitis , inflammatory bowel disease , biologic agents , disease , crohn's disease , surgery , medical therapy , intensive care medicine
Anti-tumour necrosis factor (TNF)-α therapy has revolutionized inflammatory bowel disease (IBD) treatment. Infliximab and adalimumab either as monotherapy or in combination with an immunomodulator are able to induce clinical and biological remission in patients with moderate and severe Crohn's disease (CD) and ulcerative colitis (UC). These new therapies have led to a shift in the goals of IBD management from just controlling clinical symptoms to preventing disease progression. However, despite these advances in medical therapy, surgery is still required in 30%-40% of patients with CD and 20%-30% of patients with UC at some point during their lifetime. While biologics certainly play a major role in the medical treatment of IBD, there is concern about the effects of these anti-TNF-α agents on postoperative complications and morbidity. The purpose of this article is to review the role of surgery in the treatment of IBD in the age of biologics and the impact of these medications on per-operative outcomes. In this manuscript we review the relationship between biologic agents and surgery in the treatment of IBD. We also discuss in detail the periopetative risks and complications.